Skip to Content

Quadracel Approval History

FDA Approved: Yes (First approved March 24, 2015)
Brand name: Quadracel
Generic name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV Vaccine
Dosage form: Injection
Company: Sanofi
Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Poliomyelitis Prophylaxis, Pertussis Prophylaxis

Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) is a vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.

Development History and FDA Approval Process for Quadracel

DateArticle
Mar 25, 2015Approval Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide